Overview

Vilya uses a computational biotechnology platform, built on research from the Institute of Protein Design, to create a new class of medicines. It designs drug candidates with advanced computer methods that model proteins and other biological targets, aiming to precisely influence disease biology. The company advances its own therapeutic pipeline and/or partners with pharmaceutical companies to bring these candidates to patients. What sets Vilya apart is its focus on computational drug design and protein design to rapidly generate novel medicines that target disease at the molecular level, rather than relying solely on traditional lab discovery. The main goal is to expand the set of medicines available by developing and deploying computationally designed therapeutics across multiple disease areas.